How many institutions held TELO - Telomir Pharmaceuticals, Inc. - Common Stock, no par value in Q3 2026?

2 institutional investors reported TELO - Telomir Pharmaceuticals, Inc. - Common Stock, no par value for Q3 2026. Use the holders table for investor-level position and value details.

Telomir Pharmaceuticals, Inc. - Common Stock, no par value (TELO)

Q: What does CUSIP 87975F104 represent in this 13F holders report?

CUSIP 87975F104 is the security identifier for TELO - Telomir Pharmaceuticals, Inc. - Common Stock, no par value used to aggregate holder disclosures.

CUSIP: 87975F104

Q3 2026 13F Holders as of 30 Sep 2026

Security type / class: Equity / Common Stock, no par value
Total 13F shares: 20,100
Total 13F value: $24,120
Share change: -12,019
SEC-reported price per share: $1.20
Number of holders: 2
Value change: -$15,271
Number of buys: 1
Number of sells: 1
Shares outstanding: 68,772,896

Security key

87975F104

Report period

Q3 2026

Institutions

Top holders

TELO full security history Ownership snapshot Full 13F holder table Previous quarter: Q2 2026 Telomir Pharmaceuticals, Inc. SEC filings Telomir Pharmaceuticals, Inc. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Reporting periods

Holder history for CUSIP 87975F104

Previous quarter: Q2 2026

Recent filing periods:

Q3 2026 Q2 2026 Q1 2026 Q4 2025 Q3 2025

Ownership snapshot

Top reported holders of TELO - Telomir Pharmaceuticals, Inc. - Common Stock, no par value (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader

John Paul DeJoria

Disclosed value leader

Bay Shore Trust

Comparable rows

1/15

Latest evidence

30 Jun 2026

13D/G 3/4/5 13F Lead comparable stake: 5.2% 14 rows are not safely comparable across share classes. 13D/G row: John Paul DeJoria Showing 1-6 of 15 holder rows.

Quick read

John Paul DeJoria leads the comparable SEC ownership view at 5.2%.

1 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens John Paul DeJoria's linked filing trail.

Comparable ownership Top 1

John Paul DeJoria 5.2%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows

Holder	Evidence	Ownership %	Position	12M Net Δ	As of
John Paul DeJoria	13D/G John Paul DeJoria, as trustee of the John Paul DeJoria Family Trust, and in his individual capacity 13D/G	5.2% Reported 13D/G · 30 Jun 2026	$4,514,686 3,554,871 shares	+$393,536	30 Jun 2026
Bay Shore Trust	3/4/5 10%+ Owner 3/4/5	— mixed-class rows	$20,414,715 5,631,721 shares mixed-class rows	—	21 Nov 2024
MIRA PHARMACEUTICALS, INC.	3/4/5 10%+ Owner 3/4/5	— denominator unverified	$4,823,943 3,521,127 shares	—	29 Sep 2025
Erez Aminov	3/4/5 CEO and Chairman, Director 3/4/5	— mixed-class rows	$9,515,623 9,719,710 shares mixed-class rows	—	21 May 2026
Christopher Chapman MD	3/4/5 CEO & Chairman, Director 3/4/5	— denominator unverified	$6,048,782 975,610 shares	—	08 Feb 2024
Craig Eagle	3/4/5 Director 3/4/5	— denominator unverified	$3,024,391 487,805 shares	—	08 Feb 2024

How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q3 2026

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions

20,100

Rows available

Investor	Option	Weight %	Change %	SEC-reported value	* Price	Shares	Share Change	Activity	Report Period

^* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q3 2026 vs Q2 2026 Across Filers

Q2 2026 holders

Q3 2026 holders

Holder diff

-30

Investor	Q2 2026 Shares	Q3 2026 Shares	Share Diff	Share Chg %	Q2 2026 value	Q3 2026 value	Value change	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend